RT Journal Article
SR Electronic
T1 Phase I Study Evaluating the Combination of Afatinib with Carboplatin and Pemetrexed After First-line EGFR-TKIs
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 4699
OP 4704
DO 10.21873/anticanres.12776
VO 38
IS 8
A1 SATOSHI WATANABE
A1 OU YAMAGUCHI
A1 AI MASUMOTO
A1 YURI MAENO
A1 YOSUKE KAWASHIMA
A1 OSAMU ISHIMOTO
A1 SHUNICHI SUGAWARA
A1 HIROHISA YOSHIZAWA
A1 TOSHIAKI KIKUCHI
A1 TOSHIHIRO NUKIWA
A1 KUNIHIKO KOBAYASHI
YR 2018
UL http://ar.iiarjournals.org/content/38/8/4699.abstract
AB Background/Aim: Promising reports have described the combination of first-generation epidermal growth factor receptor tyrosine-kinase inhibitors (EGFR-TKIs) with carboplatin plus pemetrexed or bevacizumab. However, no analysis of afatinib with platinum-doublet chemotherapies has been performed. Patients and Methods: We evaluated the safety and antitumor efficacy of afatinib combined with carboplatin and pemetrexed in EGFR-mutated non-small-cell lung cancer (NSCLC) patients who progressed during first-generation EGFR-TKIs. Results: Ten patients received 20 or 30 mg/day afatinib with carboplatin (area under the curve, 5) and pemetrexed (500 mg/m2). Dose-limiting toxicities included delay of afatinib ≥14 days, grade 3 diarrhea, grade 3 hypokalemia, grade 3 serum amylase increase and grade 4 thrombocytopenia. The recommended dose of afatinib was 20 mg/day in this combination therapy. Overall response rate was 30% and median progression-free survival was 13.7 months. Conclusion: This is the first study to investigate the combination of afatinib, carboplatin and pemetrexed. At the recommended dose, this combination was well tolerated and had a good clinical efficacy.